At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,371,146 enrolled
Drug / intervention
Tiotropium bromide + Olodaterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
In Brief
An observational study evaluating Tiotropium bromide + Olodaterol and Sp(t)iolto® Respimat® for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,371,146 participants across 1 site.
Detailed Summary
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
Primary CompletionApr 2020
First PostedJun 2021
TodayJul 2026
First PostedJun 15, 2021
Enrollment StartNov 15, 2019
Primary CompletionApr 14, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.0 years ago
Interventions
Tiotropium bromide + Olodateroldrug
Tiotropium bromide + Olodaterol
Sp(t)iolto® Respimat®device
Sp(t)iolto® Respimat®